Lattice Biologics Ltd
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstru… Read more
Lattice Biologics Ltd (LBLTF) - Net Assets
Latest net assets as of June 2021: $100.74K USD
Based on the latest financial reports, Lattice Biologics Ltd (LBLTF) has net assets worth $100.74K USD as of June 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($606.43K) and total liabilities ($505.69K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $100.74K |
| % of Total Assets | 16.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -2516.06% |
| Growth Volatility | 132.27 |
Lattice Biologics Ltd - Net Assets Trend (2000–2020)
This chart illustrates how Lattice Biologics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lattice Biologics Ltd (2000–2020)
The table below shows the annual net assets of Lattice Biologics Ltd from 2000 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-09-30 | $-6.40 Million | -1.40% |
| 2019-09-30 | $-6.31 Million | -18.62% |
| 2018-09-30 | $-5.32 Million | -24.85% |
| 2017-09-30 | $-4.26 Million | +27.66% |
| 2016-09-30 | $-5.89 Million | -51.36% |
| 2015-09-30 | $-3.89 Million | -716.70% |
| 2014-09-30 | $-476.65K | -31.17% |
| 2013-09-30 | $-363.39K | -526.14% |
| 2012-09-30 | $-58.04K | -121.91% |
| 2011-09-30 | $264.94K | -99.08% |
| 2010-09-30 | $28.92 Million | +3.37% |
| 2009-09-30 | $27.98 Million | +17.93% |
| 2008-09-30 | $23.72 Million | -38.74% |
| 2007-09-30 | $38.72 Million | +121.60% |
| 2006-09-30 | $17.47 Million | +129.45% |
| 2005-09-30 | $7.62 Million | +149.35% |
| 2004-09-30 | $3.05 Million | +365.95% |
| 2002-09-30 | $655.48K | -27.42% |
| 2001-09-30 | $903.06K | -2.11% |
| 2000-09-30 | $922.56K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lattice Biologics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1615395802.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.01 Million | % |
| Other Comprehensive Income | $494.15K | % |
| Total Equity | $-6.40 Million | 100.00% |
Lattice Biologics Ltd Competitors by Market Cap
The table below lists competitors of Lattice Biologics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Finger Story Co. Ltd.
KO:417180
|
$10.46K |
|
VICCO
VN:HVT
|
$10.46K |
|
ADITYA BIRLA LIFESTYLE BRANDS LTD
NSE:ABLBL
|
$10.47K |
|
Zonzia Media Inc
PINK:ZONX
|
$10.48K |
|
Hankook Steel Co. Ltd.
KQ:025890
|
$10.46K |
|
RANK GROUP (RNKA.SG)
STU:RNKA
|
$10.46K |
|
POSTNL (TNTC.SG)
STU:TNTC
|
$10.45K |
|
Ping An Guangzhou Comm Invest Guanghe Expressway
SHE:180201
|
$10.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lattice Biologics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from -6,312,802 to -6,401,127, a change of -88,325.
- Net loss of 1,483,000 reduced equity.
- Other comprehensive income increased equity by 1.
- Other factors increased equity by 1,394,674.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.48 Million | -23.17% |
| Other Comprehensive Income | $1.00 | +0.0% |
| Other Changes | $1.39 Million | +21.79% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Lattice Biologics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-09-30 | $0.04 | $0.00 | x |
| 2001-09-30 | $6.95 | $0.00 | x |
| 2002-09-30 | $3.05 | $0.00 | x |
| 2004-09-30 | $7.55 | $0.00 | x |
| 2005-09-30 | $13.32 | $0.00 | x |
| 2006-09-30 | $19.49 | $0.00 | x |
| 2007-09-30 | $26.56 | $0.00 | x |
| 2008-09-30 | $15.00 | $0.00 | x |
| 2009-09-30 | $15.58 | $0.00 | x |
| 2010-09-30 | $15.89 | $0.00 | x |
| 2011-09-30 | $0.13 | $0.00 | x |
| 2012-09-30 | $-0.03 | $0.00 | x |
| 2013-09-30 | $-0.18 | $0.00 | x |
| 2014-09-30 | $-0.24 | $0.00 | x |
| 2015-09-30 | $-0.15 | $0.00 | x |
| 2016-09-30 | $-0.12 | $0.00 | x |
| 2017-09-30 | $-0.05 | $0.00 | x |
| 2018-09-30 | $-0.06 | $0.00 | x |
| 2019-09-30 | $-0.07 | $0.00 | x |
| 2020-09-30 | $-0.06 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lattice Biologics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -60.19%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-533.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -20.49% | 0.00% | 0.00x | 1.08x | $-281.25K |
| 2001 | -65.00% | 0.00% | 0.00x | 1.01x | $-677.31K |
| 2002 | -75.48% | 0.00% | 0.00x | 1.16x | $-560.29K |
| 2004 | -21.69% | 0.00% | 0.00x | 1.18x | $-967.83K |
| 2005 | -12.55% | 0.00% | 0.00x | 1.10x | $-1.72 Million |
| 2006 | -6.73% | 0.00% | 0.00x | 1.08x | $-2.92 Million |
| 2007 | -4.38% | 0.00% | 0.00x | 1.41x | $-5.57 Million |
| 2008 | -50.87% | 0.00% | 0.00x | 1.54x | $-14.44 Million |
| 2009 | -1.32% | 0.00% | 0.00x | 1.50x | $-3.17 Million |
| 2010 | -5.48% | 0.00% | 0.00x | 1.13x | $-4.48 Million |
| 2011 | -10414.13% | 0.00% | 0.00x | 2.24x | $-27.62 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-401.20K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-452.27K |
| 2014 | 0.00% | -8.47% | 580.61x | 0.00x | $-470.37K |
| 2015 | 0.00% | -96.89% | 0.00x | 0.00x | $385.22K |
| 2016 | 0.00% | -207.83% | 0.82x | 0.00x | $-7.26 Million |
| 2017 | 0.00% | -55.68% | 0.79x | 0.00x | $-1.10 Million |
| 2018 | 0.00% | -106.58% | 0.38x | 0.00x | $-698.81K |
| 2019 | 0.00% | -46.23% | 0.96x | 0.00x | $-380.72K |
| 2020 | 0.00% | -60.19% | 0.82x | 0.00x | $-842.89K |
Industry Comparison
This section compares Lattice Biologics Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lattice Biologics Ltd (LBLTF) | $100.74K | -20.49% | 5.02x | $10.46K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |